维生素K拮抗剂与新型口服抗凝药和房颤患者癌症发病风险的关联
该研究基于人群数据库构建倾向加权队列,纳入39,989例非瓣膜性房颤患者,比较启动VKA或DOAC后随访至多5年(中位2.94年)的癌症发生率。任何癌症发病率DOAC组为12.45/1000人年,VKA组为14.55/1000人年,校正HR 1.16(95%CI 1.02-1.32);特定癌种未见差异,男性亚组VKA与结肠癌风险降低相关(HR 0.68,95%CI 0.48-0.96)。
要点
- VKA相较DOAC未显示降低总体癌症发病风险,任何癌症校正HR 1.16(95%CI 1.02-1.32)。
- 肺癌、结肠癌、前列腺癌、膀胱癌和乳腺癌等特定癌种发生率两组间无差异。
- 男性亚组中VKA与结肠癌风险降低相关(HR 0.68,95%CI 0.48-0.96),需谨慎解读。
核心结论
- 在非瓣膜性房颤真实世界队列中,与DOAC相比,VKA未显示化学保护作用。
研究设计与样本
- 基于人群数据库的倾向加权队列研究,纳入39,989例非瓣膜性房颤患者,随访至多5年(中位2.94年)。
- 按起始治疗分为VKA队列(31,200例,78.0%)和DOAC队列,起始定义为前12个月无暴露的新处方。
主要发现
- 任何癌症发病率DOAC组为12.45/1000人年,VKA组为14.55/1000人年,校正HR 1.16(95%CI 1.02-1.32)。
- 肺癌HR 1.28(95%CI 0.89-1.83)、结肠癌HR 0.84(95%CI 0.62-1.13)、前列腺癌HR 1.40(95%CI 0.94-2.10)、膀胱癌HR 1.07(95%CI 0.76-1.52)、乳腺癌HR 1.05(95%CI 0.66-1.69),均无差异。
- 敏感性分析结果相似;亚组分析总体一致,但男性亚组VKA与结肠癌风险降低相关(HR 0.68,95%CI 0.48-0.96)。
临床怎么用
- 为房颤患者选择VKA或DOAC时,不应以降低癌症风险作为选择VKA的依据。
- 男性房颤患者VKA与结肠癌风险降低的亚组结果属探索性,不宜据此改变抗凝决策。
局限性
- 为观察性队列研究,虽采用倾向加权,仍可能存在残余混杂。
- 男性结肠癌亚组结果为亚组分析,需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The association between the use of vitamin K antagonists (VKAs) and cancer risk reduction remains unclear. We aimed to assess the association between the use of VKAs or direct oral anticoagulants (DOACs) and the incidence of cancer in a large cohort of patients with atrial fibrillation (AF) by means of a population-based, propensity-weighted cohort study using population-wide databases including patients diagnosed with nonvalvular AF (NVAF) followed for up of 5 years (median 2.94 years). We created two cohorts based on the initiation therapy (VKA or DOAC). Initiation with VKA or DOAC was defined as filling a prescription with no previous exposure in the preceding 12 months. Cancer diagnoses of any type and for specific tumors (lung, colon, prostate, bladder, and breast). We included 39,989 patients, 31,200 (78.0%) in the VKA cohort. Incidence rate for any cancer was 12.45 per 1,000 person-year in the DOAC cohort vs. 14.55 in the VKA cohort (adjusted hazard ratio (HR): 1.16, 95% confidence interval (CI): 1.02-1.32). In secondary outcomes, no differences were found for specific types of cancer, such as lung (HR: 1.28, CI: 0.89-1.83), colon (HR: 0.84, CI: 0.62-1.13), prostate (HR: 1.40, CI: 0.94-2.10), bladder (HR: 1.07, CI: 0.76-1.52), and breast (HR: 1.05, CI: 0.66-1.69). Sensitivity analyses yielded similar results. Subgroup analyses also produced consistent findings, except for men, for whom VKA was associated with a lower risk of colon cancer (HR: 0.68, 95% CI: 0.48-0.96). Our results do not confirm a chemoprotective effect of VKA when compared with DOAC in a large, real-world cohort of patients with NVAF followed for up to 5 years.
引用
- Iftimi AA, Rodríguez-Bernal CL, Peiró S, et al. Association of Vitamin K and Non-Vitamin K Oral Anticoagulant Use and Cancer Incidence in Atrial Fibrillation Patients. Clin Pharmacol Ther. 2021. PMID: 34242404. doi:10.1002/cpt.2362
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。